Effect and safety analysis of amiodarone and lidocaine on cardiac function in patients with chronic heart failure
Objective:To compare the effects of amiodarone and lidocaine on cardiac function and safety in patients with chronic heart failure(CHF).Methods:The clinical data of 98 patients with chronic heart failure from March 2021 to March 2023 were retrospectively collected.According to different treatment regimens,patients were divided into control group(lidocaine treatment,49 cases)and observation group(amiodarone treatment,49 cases).The therapeutic effect,clinical indicators[heart rate,systolic blood pressure,diastolic blood pressure],cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular posterior wall thickness(LVPwd)],myocardial injury markers[cardiac troponin-I(cTnI),creatine kinase isoenzymes-MB(CK-MB),brain natriuretic peptide(BNP);fibroblast growth factor 2(FGF2)]and safety of the two groups were analyzed and compared.Results:The total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,the heart rate,systolic blood pressure,diastolic blood pressure,pre-ventricular systolic count,QTd,LVPwd and LVEDD in observation group were significantly lower than those in control group,and QTc and LVEF were significantly higher than those in control group(P<0.05).After treatment,CK-MB,BNP,FGF2 and cTnI in observation group were significantly decreased compared with control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Amiodarone in the treatment of CHF patients with arrhythmia can significantly improve the cardiac function of patients,alleviate myocardial injury and clinical symptoms,the effect is better than lidocaine,and the safety is higher.
NETL
NSTL
万方数据
维普
